Author:
Jennings Gary T.,Bachmann Martin F.
Abstract
AbstractVirus-like particles are supra-molecular assemblages, usually icosahedral or rod-like structures. They incorporate key immunologic features of viruses which include repetitive surfaces, particulate structures and induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors. They carry no replicative genetic information and can be produced recombinantly in large scale. Virus-like particles thus represent a safe and effective vaccine platform for inducing potent B- and T-cell responses. In addition to being effective vaccines against the corresponding virus from which they are derived, virus-like particles can also be used to present foreign epitopes to the immune system. This can be achieved by genetic fusion or chemical conjugation. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases. Towards this end, virus-like particles have been used to induce autoantibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer's disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development.
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference78 articles.
1. and Mur - phy Passively transferred monoclonal antibody to the protein inhibits influenza A virus replication in mice;Treanor;Virol,1990
2. Size - dependent immunogenicity : therapeutic and protective prop - erties of nano - vaccines against tumors;Fifis;Immunol,2004
3. Virus - like particles : flexible platforms for vaccine development Expert Rev Jennings and Bachmann Article in press - uncorrected proof Induction of autoantibodies to mouse CCR with recombinant papil - lomavirus particles;Chackerian;Vaccines Proc Natl Acad Sci USA,2007
4. Expression , self - assembly , and antigenicity of the Norwalk virus capsid protein;Jiang;J Virol,1992
5. Renin - angiotensin vaccine : old story , new project efficacy versus safety ( Lond );Michel;Clin Sci,2004
Cited by
320 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献